Graceway announced that Zyclara (imiquimod) Cream 2.5% has been approved for the treatment of actinic keratosis on the face or balding scalp. This approval was based on data from clinical studies which demonstrated that of the four double-blind studies conducted to evaluate Zyclara 2.5% or 3.75% versus placebo, patients applying Zyclara 2.5% on a two weeks on, two weeks off, two weeks on dosing cycle experienced the least amount of local skin reactions from any of the treatment groups. In addition, 31% of patients using Zyclara 2.5% cream had complete clearance of actinic keratoses versus 6% for the placebo group.

Zyclara is already available in a 3.75% strength formulation. Zyclara 3.75% is also indicated for the treatment of genital warts.

For more information call (800) 328-0255 or visit